However, a recent study by Tantawy et al., showed that in CLL cells, MCL-1 antagonists disrupted MCL-1-related ubiquitin ligases, thus disabling MCL-1 degradation and promoting its accumulation.30 Whether an analogous mechanism is operative in AML cells remains to be determined. The gene discussed is MCL1; the disease is B-cell chronic lymphocytic leukemia.